posit reiter buy rais
therapeut announc posit data pivot phase
momentum trial treatment migrain met
regulatori co-primari endpoint significantli improv migrain
pain bothersom symptom compar placebo
momentum phase trial also met key secondari
endpoint show statist signific superior activ
compar rizatriptan sustain freedom migrain pain
axsom candid met co-primari endpoint demonstr
high statist signific greater percentag patient vs
placebo achiev pain freedom versu
absenc bothersom symptom versu
two hour dose superior rizatriptan moseic
meloxicam compon contribut establish specifi
special protocol assess spa agreed-upon fda
greater percentag patient achiev sustain pain
freedom two hour dose vs rizatriptan
moseic meloxicam well placebo
respect respect vs
vantag point data firmli establish axsom
compani three major potenti shot goal
major depress disord mdd migrain
narcolepsi view momentum data substanti
increas probabl approv success commerci
accordingli increas probabl approv
prior wake posit momentum
data anticip value-driv catalyst come
month includ top-lin result intercept trial
reiter buy rate rais target
previou per share reflect increas
valuat vs prior view axsom share
despit recent massiv run-upcontinu look under-valued
edg vs activ compar similar work
axsom demonstr superior proprietari
combin agent vs activ compar migrain
believ ought view crucial differenti factor
facilit regulatori approv sinc axsom
clearli shown benefit combin therapi vs constitu
greater sustain migrain pain relief vs placebo
rizatriptan translat signific reduct rescu
medic use compar placebo rizatriptan
percentag patient experienc sustain pain relief two
hour dose vs placebo
rizatriptan respect vs
sustain pain relief hour also experienc
statist significantli greater proport patient
vs placebo rizatriptan patient
respect versu rescu medic use
patient vs placebo rizatriptan
patient group vs
definit distribut analyst rate analyst certif disclosur pleas refer page report
multipl addit secondari endpoint metposs read-through intercept data provid rapid relief
migrain pain percentag patient achiev pain relief numer greater rizatriptan
everi time point measur start minut statist significantli greater rizatriptan minut
proport patient experienc pain relief hour dose vs
rizatriptan placebo respect vs addit statist significantli
superior rizatriptan sever secondari endpoint includ patient global impress chang pgi-c
return normal function hour safe well-toler trial common
advers event nausea dizzi somnol none occur rate greater placebo
one seriou advers event arm deem unrel studi drug view
data clearli indic multipl frontsought consid superior exist triptan therapi thu
may posit front-lin treatment migrain patient rapid onset action particularli noteworthi
vantag point given rizatriptan statu fastest-act triptan current avail believ strong show
across multipl paramet momentum trial ought bode well intercept studi particularli sinc
intercept evalu earlier migrain treatment remind intercept random double-blind
placebo-control studi evalu earli treatment migrain contrast momentum trial
patient histori inadequ respons treat migrain attack becom moder sever intens
intercept trial patient administ earliest sign migrain pain feel earli deploy
ought suit sinc triptan gener effect administ earlier evolut migrain attack
furthermor would point oral formul composit includ well-known widely-us triptan
drug rizatriptan may posit favor vs recently-launch late-stag anti-migrain drug notabl anti-
calcitonin gene-rel peptid anti-cgrp agent drug develop prevent migrain attack
occur note also like util treatment on-going attack well vantag point
conveni advantag vs inject anti-cgrp agent aimovig erenumab-aoo
rate ajovi fremanezumab-vfrm teva pharmaceut industri teva rate eptinezumab
alder biopharmaceut recent acquir lundbeck a/ hluki rate believ
would probabl cost substanti less agent sinc monoclon antibodi given robust
efficaci profil feel also abl hold vs oral anti-cgrp agent includ ubrelvi
ubrogep may well util wide due physician familiar mechan action
still multipl addit value-driv catalyst around corner note upcom clinic readout
top-lin data intercept studi earli treatment migrain slate releas come week
 top-lin data pivot trial treatment-resist depress trd also slate
releas come week earli top-lin data phase trial
alzheim diseas ad -relat agit slate releas view posit data studi could
impact valuat still feel axsom current market cap still reflect substanti credit mdd
trd possibl migrain pipelin program remain compar ignor valuat still
accord likelihood approv migrain await result momentum intercept
pivot studi likelihood approv smoke cessat investor note axsom could
posit file two new drug applic nda mdd migrainebefor end
possibl build next great neurolog compani field central nervou system neuropsychiatr
disord histor proven extrem difficult drug develop multipl late-stag failur litter landscap
believ solid data ascend gemini concert axsom solidli proven worth highli
challeng domain view axsom could well grow firm like forest laboratori acquir actavi
subsequ allergan plc process integr rate juli
much forest success achiev antidepress arena commerci drug celexa
citalopram lexapro escitalopram viibryd vilazodon lexapro alon reach peak sale prior patent
expiri believ axsom could easili reach peak sale similar forest laboratori prior acquisit
 around prior impact gener erosionbas sole mdd migrain
narcolepsi furthermor feel axsom would multipl advantag vs forest time acquisitiona
much concentr market product portfolio sole focu neurolog much smaller expens base far longer
market exclus base term issu patent thu believ consider potenti long-term
sustain growth may deliv substanti upsid
valuat risk util risk-adjust net present valu rnpv approach assess axsom share appli
discount rate futur cash flow along effect tax rate sale market rate approach
yield total firm valu roughli price per share roughli given fully-dilut share outstand
factor issuanc share common stock includ share recent
financ exercis currently-outstand option warrant risk includ limit delay
obtain clinic data on-going mid- late-stag studi neg data readout on-going trial includ
intercept inabl secur regulatori approv
pipelin candid lower-than-project commerci success pipelin program post-approv due higher-than-
expect competit pressur lower-than-anticip market penetr medium- long-term dilut risk
thousand except per share data
compani report wainwright co estim
revenue- total revenue- expensesresearch develop sell gener oper loss interest amort debt tax credit- chang fair valu warrant net incom net incom loss per share net incom loss per share weight averag number share outstand weight averag number share outstand axsom inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc axsm-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
raghuram selvaraju ph certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli
relat specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur axsom
therapeut inc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc non-invest bank servic
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
 wainwright co llc manag co-manag public offer secur inc
firm make market axsom inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
